Navigation Links
Telik Announces Preclinical Presentations at AACR Annual Meeting
Date:4/7/2008

PALO ALTO, Calif., April 7, 2008 /PRNewswire-FirstCall/ -- Telik, Inc. (Nasdaq: TELK) announced that four abstracts highlighting results from its Research and Development programs will be presented at the 99th annual meeting of the American Association for Cancer Research (AACR) in San Diego.
Details of the presentations are as follows:

-- Identification and Characterization of Novel Tyrosine Kinase Inhibitors

Targeting Vascular Endothelial Growth Factor Receptor 2; Sunday, April

13, 2008, 1:00 - 5:00pm; Experimental and Molecular Therapeutics 10;

Abstract # 1439

-- Mechanism of Induction of Apoptosis by TLK199 (Telintra(R)) in Human

Leukemia Cell Lines; Monday, April 14, 2008, 8:00am - 12noon;

Experimental and Molecular Therapeutics 10; Abstract # 2270

-- Identification of a Novel Class of Nonpeptidyl Small-Molecule

Inhibitors of the Human Proteasome; Monday, April 14, 2008,

1:00 - 5:00pm; Experimental and Molecular Therapeutics 28;

Abstract # 3271

-- Target-Related Affinity Profiling (TRAP(R)): Efficient Cancer Drug

Discovery at Telik; Tuesday, April 15, 2008; 1:00 - 5:00pm; Cancer

Chemistry 11; Abstract # 4754

Telik, Inc. of Palo Alto, CA, is a biopharmaceutical company focused on discovering, developing and commercializing novel small molecule drugs to treat serious diseases. The company's most advanced investigational drug candidates in clinical development are TELINTRA, a modified glutathione analog for the treatment of cytopenias due to myelodysplastic syndrome or chemotherapy, and TELCYTA(R), a tumor-activated prodrug for the treatment of advanced ovarian cancer and non-small cell lung cancer. Telik's product candidates were discovered using its proprietary drug discovery technology, TRAP, which enables the rapid and efficient discovery of small molecule drug candidates.

TELIK, the Telik logo, TELCYTA, TELINTRA and TRAP are trademarks or registered trademarks of Telik, Inc.


'/>"/>
SOURCE Telik, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Telik Reports Positive Results From Phase 1 Dose-Escalation Study of TELINTRA Tablets in Myelodysplastic Syndrome
2. DARA Announces Information in Compliance with NASDAQ Rules
3. Journey Lite of Thousand Oaks Announces Special Spring Price Discount In Response to Effects of Softening Economy on Patients Pocketbooks
4. VA Announces SGLI and VGLI Premium Reductions
5. London Luxury LLC Announces Exclusive Partnership with Cupron, Inc., to Develop Innovative Copper-Infused Bed and Bath Products
6. Boston Scientific Announces Appointment of Timothy Pratt as General Counsel
7. Accuri Cytometers Announces Commercial Launch of Revolutionary Accuri C6 Flow Cytometer(TM) System
8. Haemacure Announces Details of its Annual General and Special Meeting of Shareholders
9. QED International Associates Announces Changes to the HealthShares(TM) Cardio Devices Index (As Revised)
10. Smart Balance Announces Sales Organization Appointments
11. Global Action Board of Directors Announces Addition of Newest Member, Robert Hernreich
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... ... its strategic partnership with Connance, a healthcare industry leader providing predictive analytics ... proprietary technology combine to provide health systems, hospitals and ambulatory surgical centers ...
(Date:6/26/2016)... ... , ... Pixel Film Studios Released ProSlice Levels, a Media Slicing Effect ... a whole new perspective by using the title layers in ProSlice Levels to ... ProSlice Levels contains over 30 Different presets to choose from. FCPX users ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery ... of Mohs Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , ... for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as a method ... —Johnson is one of the first doctors to perform the treatment. Orthobiologics are ...
(Date:6/24/2016)... ... , ... June 19, 2016 is World Sickle Cell Observance Day. In an ... of holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued a ... Cell Disease (SCD) is a disorder of the red blood cells, which can cause ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... June 24, 2016 According to ... Type (Standard Pen Needles, Safety Pen Needles), Needle Length ... Growth Hormone), Mode of Purchase (Retail, Non-Retail) - Trends ... report studies the market for the forecast period of ... USD 2.81 Billion by 2021 from USD 1.65 Billion ...
(Date:6/23/2016)... , June 23, 2016 Research and ... Global Market - Forecast to 2022" report to their ... treatment method for the patients with kidney failure, it replaces ... fluid from the patient,s blood and thus the treatment helps ... and chloride in balance. Increasing number of ...
(Date:6/23/2016)... 2016 Research and Markets has announced ... Analysis 2016 - Forecast to 2022" report to their ... contains up to date financial data derived from varied research ... trends with potential impact on the market during the next ... which comprises of sub markets, regional and country level analysis. ...
Breaking Medicine Technology: